Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




World-First Angiogenesis Reversal Could Help Treat Tumors

By Biotechdaily staff writers
Posted on 12 May 2008
Researchers investigating how blood vessel growth keeps tumors alive have made a world-first discovery that could increase the chances of effectively treating life-threatening tumors. More...


Western Australian Institute for Medical Research (WAIMR; Perth) associate professor Dr. Ruth Ganss and her team discovered that a gene called RGS5 can reverse angiogenesis--the growth of blood vessels inside the tumor. This finding was published in the April 17, 2008, issue of the journal Nature.

"It's the uncontrolled growth of blood vessels and the formation of abnormal blood vessels inside tumors that ‘feed' them, allowing them to grow and stopping the immune system from wiping out the tumor,” said Dr. Ganss. "What we've shown is that RGS5 is a master gene in angiogenesis and that when it is removed, angiogenesis reverses and the blood vessels in tumors appear more normal. Importantly, this normalization changes the tumor environment in a way that improves immune cell entry, meaning tumors can be destroyed and improving survival rates in laboratory tests.”

Reversing abnormal vessel growth represents a fresh approach to tackling angiogenesis, with most current research focusing on how to block or kill tumor-feeding blood vessels.

"We've long-suspected this research would deliver advances in knowledge about what impacts tumor growth and this publication recognizes the innovation and importance of our work,” said Dr. Ganss. "By understanding what is actually going on in the tumor itself, the ultimate hope is that we'll be able to work on making current therapeutic approaches even more successful and reducing side effects of them.”

Earlier in April 2008, a second article by Dr. Ganss and her team was published in The Journal of Clinical Investigation that describes how tumors can be attacked by the immune system with fewer side effects. "This discovery involves targeting tumors with inflammatory substances that change the environment, so immune cells can attack the tumor through blood vessels more effectively and lessen the amount of toxins going elsewhere in the body,” she said.

WAIMR director Prof. Peter Klinken praised Dr. Ganss' team reported that their work was serving to further put WA on the scientific world map. "This breakthrough is one of the most significant discoveries to come out of WAIMR. The potential for this new knowledge to positively impact the lives of cancer patients in the future is very exciting,” he said. "The fact that this breakthrough has come during our 10-year anniversary celebrations is just fantastic.”


Related Links:
Western Australian Institute for Medical Research

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.